Product Information
GS ALLER-EASE 180 MG TABLET is a generic product labeled by L. Perrigo Company, priced at $0.2302 per EA under NDC 00113084795. Its NADAC has been published 158 times since Sep 27, 2023.
FDA first approved this application on Feb 24, 2020.
Strength
180 mg/1
Manufacturer
L. Perrigo CompanyNDC
00113084795
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FEXOFENADINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA212971FDA Approved
2/24/2020
On Market Since
9/10/2021
Pharmacological Classes
Price Statistics
The NADAC for GS ALLER-EASE 180 MG TABLET has been published 158 times since Sep 27, 2023, and over the history we have for it it has declined 12.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2302 per EA |
|---|---|
| All-time high | $0.2846 (Nov 15, 2023) |
| All-time low | $0.2079 (Nov 20, 2024) |
| 52-week high | $0.2728 |
| 52-week low | $0.2302 |
| Median price | $0.2571 |
| Average price | $0.2556 |
| Largest weekly change | -24.0% (Nov 20, 2024) |
| Weeks tracked | 158 |
| Tracking since | Sep 27, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
L. Perrigo Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fexofenadine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GS ALLER-EASE 180 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GS ALLER-EASE 180 MG TABLET, manufactured by L. Perrigo Company, is $0.2302 per EA (NDC 00113084795), effective Sep 30, 2026.
How has the price of GS ALLER-EASE 180 MG TABLET changed over time?
Over the history we have for it, the NADAC for GS ALLER-EASE 180 MG TABLET has declined 12.9%. It has been tracked across 158 weekly CMS publications since Sep 27, 2023.
What are the highest and lowest recorded NADAC prices for GS ALLER-EASE 180 MG TABLET?
Since Sep 27, 2023, the NADAC for GS ALLER-EASE 180 MG TABLET has ranged from a low of $0.2079 (Nov 20, 2024) to a high of $0.2846 (Nov 15, 2023), with a median of $0.2571 per EA.
Are there cheaper alternatives to GS ALLER-EASE 180 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as GS ALLER-EASE 180 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures GS ALLER-EASE 180 MG TABLET?
GS ALLER-EASE 180 MG TABLET (NDC 00113084795) is labeled by L. Perrigo Company, and CMS classifies it as a generic product.